

#2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Edward P. Cohen Examiner: to be assigned
Serial No.: Unassigned Docket: 10464a
Filed: Herewith Dated: March 10, 2000
For: CANCER IMMUNOTHERAPY WITH
SEMI-ALLOGENEIC CELLS

16678 U.S. PTO
09/522716
03/10/00

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following disclosures, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. D.L. Shawler et al. (1997) "Gene Therapy Approaches to Enhance Antitumor Immunity" *Advances in Pharmacology* 40: 309-337;
2. T. Boon et al. (1992) "Identification of Tumour Rejection Antigens Recognized By T-Lymphocytes" *Cancer Surveys* 13: 23-37;

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number: EL089369942US
Date of Deposit: March 10, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231.

Dated: March 10, 2000

Michelle Spina

3. T. Boon (1993) "Tumor Antigens Recognized By Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy" *Int. J. Cancer* 54: 177-180;
4. T. Boon (1992) "Toward a Genetic Analysis of Tumor Rejection Antigens" *Advances in Cancer Research* 58: 177-209;
5. J. Vieweg and E. Gilboa (1995) "Considerations for the Use of Cytokine-Secreting Tumor Cell Preparations for Cancer Treatment" *Cancer Investigation*: 13 (2): 193-201;
6. K.M. Hui et al. (1989) "Tumor Rejection Mediated by Transfection With Allogeneic Class I Histocompatibility Gene" *The Journal of Immunology* 143 (11): 3835-3843;
7. S. Ostrand-Rosenberg et al. (1991) "Tumor-Specific Immunity Can Be Enhanced By Transfection of Tumor Cells With Syngeneic MHC-Class-II Genes or Allogeneic MHC-Class-I Genes" *Int. J. Cancer* 6 (Sup.): 61-68;
8. J.A. Roth and R.J. Cristiano (1997) "Gene Therapy for Cancer: What Have We Done and Where Are We Going?" *Journal of the National Cancer Institute* 89 (1): 21-39;
9. T.S. Kim and E.P. Cohen (1994) "MHC Antigen Expression By Melanomas Recovered From Mice Treated With Allogeneic Mouse Fibroblasts Genetically Modified for Interleukin-2 Secretion and the Expression of Melanoma-associated Antigens" *Cancer Immunol. Immunother.* (1994) 38: 185-193;
10. T.S. Kim et al. (1992) "Immunity to B16 Melanoma in Mice Immunized With IL-2-secreting Allogeneic Mouse Fibroblasts Expressing Melanoma-associated Antigens" *Int. J. Cancer* 51: 283-289;
11. E.P. Cohen and T.S. Kim (1994) "Neoplastic Cells That Express Low Levels of MHC Class I Determinants Escape Host Immunity" *Seminars in Cancer Biology* 5: 419-428;

12. T. Itaya et al. (1987) "Xenogenization of a Mouse Lung Carcinoma (3LL) By Transfection With An Allogeneic Class I Major Histocompatibility Complex Gene (H-2L^d)¹" *Cancer Research* 47: 3136-3140;
13. T. Lichtor et al. (1995) "Prolonged Survival of Mice With Glioma Injected Intracerebrally With Double Cytokine-secreting Cells" *J. Neurosurg.* 83: 1038-1044;
14. P. van der Bruggen et al. (1991) "A Gene Encoding an Antigen Recognized By Cytolytic T Lymphocytes on a Human Melanoma" *Science* 254: 1643-1647;
15. U.S. Patent No. 5,674,486, to Sobol et al.;
16. D.L. Toffaletti et al. (1983) "Augmentation of Syngeneic Tumor-specific Immunity By Semiallogeneic Cells Hybrids" *The Journal of Immunology* 130 (6): 2982-2986;
17. M.I. Colnaghi (1975) "Histocompatibility Antigens Acting as Helper Determinants for Tumor-associated Antigens of Murine Lymphosarcoma" *Eur. J. Immunol.* 5: 241-245;
18. W. Xu et al. (1998) "Co-expression of Immunogenic Determinants by the Same Cellular Immunogen is Required for the Optimum Immunotherapeutic Benefit in Mice With Melanoma" *Cancer Immunol. Immunother.* 45: 217-224;
19. D.R. Wang et al. (1985) "Leukemia x Fibroblast Hybrid Cells Prolong the Lives of Leukemic Mice" *Eur. J. Cancer Clin. Oncol.* 21 (5): 637-645;
20. W. Liang and E.P. Cohen (1976) "Resistance to Murine Leukemia in Mice Rejecting Syngeneic Somatic Hybrid Cells" *The Journal of Immunology* 116 (3): 623-626;
21. W. Liang and E.P. Cohen (1977) "Activation of Specific Cellular Immunity Toward Murine Leukemia in Mice Rejecting Syngeneic Somatic Hybrid Cells" *The Journal of Immunology* 119 (3): 1054-1060;

22. B.S. Kim et al. (1979) "Tumor-specific Immunity Induced by Somatic Hybrids" *The Journal of Immunology* 123 (2): 733-738;
23. S.L. Garber et al. (1984) "Persistence of the Immunoprotective Effects of Leukemia x Fibroblast Hybrid Cells Toward Leukemia in Histocompatible Mice" *Leukemia Research* 8 (2): 255-266;
24. R. Slomski et al. (1984) "Surface Antigens of Immunoprotective Leukaemia x Fibroblast Hybrid Cells Which Have Lost Malignant Properties in Histocompatible Mice Differ From the Malignant Parental Cells" *Immunology* 52: 281-290;
25. W. Liang and E.P. Cohen (1977) "Resistance to Murine Leukemia in Mice Receiving Simultaneous Injections of Syngeneic Hybrid and Parental Neoplastic Cells" *The Journal of Immunology* 118 (3): 903-908;
26. J. Jami and E. Ritz (1975) "Tumor-associated Transplantation Antigens in Immune Rejection of Mouse Malignant Cell Hybrids" *Proc. Nat. Acad. Sci. USA* 72 (6): 2130-2134;
27. J. Jami and E. Ritz (1973) "Nonmalignancy of Hybrids Derived From Two Mouse Malignant Cells. I. Hybrids Between L1210 Leukemia Cells and Malignant L. Cells" *Journal of the National Cancer Institute* 51 (5): 1647-1653;
28. S.E. Karp et al. (1993) "Cytokine Secretion By Genetically Modified Nonimmunogeneic Murine Fibrosarcoma Tumor Inhibition by IL-2 but Not Tumor Necrosis Factor" *The Journal of Immunology* 150 (3): 896-908;
29. T.S. Kim et al. (1993) "Independent Cell Types Are Involved in the Induction of Antimelanoma Responses in C57BL/6 Mice Immunized with Interleukin-2-secreting Allogeneic Mouse Fibroblasts Expressing Melanoma-associated Antigens" *Journal of Immunotherapy* 14: 298-304;
30. T.S. Kim et al. (1993) "Immunization With Interleukin-2-secreting Allogeneic Mouse Fibroblasts Expressing Melanoma-associated

Antigens Prolongs the Survival of Mice With Melanoma" *Int. J. Cancer* 55: 865-872;

31. D.M. Pardoll (1993) "Cancer Vaccines" *Immunology Today* 14 (6): 310-316;
32. D. Pardoll (1992) "New Strategies for Active Immunotherapy With Genetically Engineered Tumor Cells" *Current Opinion in Immunology* 4: 619-623;
33. A. Porgador et al. (1993) "Antimetastatic Vaccination of Tumor-bearing Mice With Two Types of IFN- λ Gene-inserted Tumor Cells" *The Journal of Immunology* 150 (4): 1458-1470;
34. A. Porgador et al. (1993) "Anti-metastatic Vaccination of Tumor-bearing Mice With IL-2-Gene-inserted Tumor Cells" *Int. J. Cancer* 53: 471-477;
35. A. Porgador et al. (1992) "Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence Against Parental Metastatic Cells" *Cancer Research* 52: 3679-3686;
36. S.A. Rosenberg (1992) "The Immunotherapy and Gene Therapy of Cancer" *Journal of Clinical Oncology* 10 (2): 180-199;
37. S.J. Russell et al. (1991) "Decreased Tumorigenicity of a Transplantable Rat Sarcoma Following Transfer and Expression of an IL-2 cDNA" *Int. J. Cancer* 47: 244-251;
38. J.S. Weber and S.A. Rosenberg (1988) "Modulation of Murine Tumor Major Histocompatibility Antigens by Cytokines *in Vivo* and *in Vitro*" *Cancer Research* 48: 5818-5824;
39. G. Yamada et al. (1987) "Retroviral Expression of the Human IL-2 Gene in a Murine T-Cell Line Results in Cell Growth Autonomy and Tumorigenicity" *The EMBO Journal* 6 (9): 2705-2709;
40. M. Zöller et al. (1988) "Interferon-gamma Treatment of B16 Melanoma Cells: Opposing Effects for Non-adaptive and Adaptive Immune Defense and

its Reflection by Metastatic Spread" *Int. J. Cancer* 41: 256-266;

41. M. Kasai et al. (1980) "A Glycolipid on the Surface of Mouse Natural Killer Cells" *Eur. J. Immunol.* 10: 175-180;
42. H.F. Oettgen et al. (1990) "Serologic Analysis of Human Cancer" *Immunol. Allergy Clin. North. Am.* 10 (4): 607-637;
43. M. Sarmiento et al. (1985) "IgG or IgM Monoclonal Antibodies Reactive With Different Determinants on the Molecular Complex Bearing LYT 2 Antigen Block T Cell-mediated Cytolysis in the Absence of Complement" *J. Immunol.* 125 (6): 2665-2672;
44. B. Sugden et al. (1985) "A Vector That Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" *Mol. Cell. Biol.* 5 (2): 410-413;
45. C. Traversari et al. (1992) "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E" *J. Exp. Med.* 176: 1453-1457;
46. R.G. Vile and I.R. Hart (1993) "In Vitro and in Vivo Targeting of Gene Expression to Melanoma Cells" *Cancer Res.* 53: 962-967;
47. M. Wigler et al. (1978) "Biochemical Transfer of Single-copy Eucaryotic Genes Using Total Cellular DNA as Donor" *Cell* 14: 725-731;
48. H.E. Young et al. (1995) "Mesenchymal Stem Cells Reside Within the Connective Tissues of Many Organs" *Dev. Dynamics* 202: 137-144;
49. J. Vieweg et al. (1995) "Considerations for the Use of Cytokine-secreting Tumour Cell Preparations for Cancer Treatment" *Cancer Investigation* 13 (2): 193-201;
50. X. Wu et al. (1998) "Co-expression of Immunogenic Determinants by the Same Cellular Immunogen is Required for the Optimum Immunotherapeutic Benefit in Mice Melanoma" *Cancer Immunol. Immunother.* 45 (5): 217-224;


51. D.A. Newton et al. (1997) "Melanoma Cell Hybrids as Cancer Vaccines" *Proceedings of the Annual Meeting of the American Association for Cancer Research* 38: 398;
52. D.L. Toffaletti et al. (1983) "Augmentation of Syngeneic Tumor-specific Immunity by Semiallogeneic Cell Hybrids" *Journal of Immunology* 130 (6): 2982-2986;
53. B. Payelle et al. (1981) "Adoptive Transfer of Immunity Induced by Semi-allogeneic Hybrid Cells Against Murine Fibrosarcoma" *Int. J. Cancer* 27: 783-788;
54. U.S. Patent No. 5,750,102, to Eisenbach et al.; and
55. O. Mandelboim et al. (1995) "Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells" *Gene Therapy* 2: 757-765.

Pursuant to 37 C.F.R. §1.98(d), copies of publications are not provided, for Reference Nos. 1-40, as these references were previously submitted to the Examiner in connection with the parent case, Serial Number 09/016,528 filed on April 30, 1998. Copies of publications are not provided for Reference Nos. 41-48, as these references were previously submitted to the Examiner in connection with the parent case, Serial Number 09/016,528 filed on May 5, 1998. Copies of publications are not provided for Reference Nos. 49-53, as these references were previously submitted to the Examiner in connection with the parent case, Serial Number 09/016,528 filed on October 29, 1998. Applicant is submitting copies of publications for Reference Nos. 54 and 55.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no petition, certification or fee is required.

Consideration of this Information Disclosure Statement is respectfully requested.

Respectfully submitted,



Leopold Presser
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
LP/XZ:ab